Design, synthesis, in silico pharmacokinetics prediction and biological evaluation of 1,4-dihydroindeno[1,2-c]pyrazole chalcone as EGFR /Akt pathway inhibitors
4-dihydroindeno[1,2-c]pyrazole chalcone (12a-o) were designed, synthesized and evaluated for their antiproliferative activity against MCF7, A549, MDA-MB-231, HCT116 and SKBR3 human cancercell lines. Among them, 12h, 12l and 12m showed IC50 values: 3.82, 5.33 and 4.21 μM, respectively, on A549 cell with respect to the positive control, Erlotinib (IC50 value: 10.26 μM). Detailed biological assays showed accumulation
为了开发有效和选择性的抗癌药,设计,合成了一系列15种1,4-二氢茚并[1,2- c ]吡唑查尔酮(12a-o)缀合物,并评估了其对MCF7,A549的抗增殖活性,MDA-MB-231,HCT116和SKBR3人癌细胞系。其中,12小时,12升和12米表明IC 50值:3.82,5.33和4.21μM,分别在相对于阳性对照A549细胞,埃罗替尼(IC 50值:10.26μM)。详细的生物学分析显示有丝分裂细胞在G2 / M期积累。此外,蛋白质印迹分析和免疫荧光研究显示,EGFR和Akt途径受到抑制。在计算机上也进行了计算机研究,以预测这些结合物的结合方式和药代动力学参数。